Cabaletta Bio (CABA) Total Liabilities (2018 - 2026)
Cabaletta Bio (CABA) posted quarterly Total Liabilities of $53.0 million for Q4 2025, up 62.12% year-over-year from $32.7 million in Q4 2024, and up 5.45% quarter-over-quarter from $50.3 million in Q3 2025.
Cabaletta Bio (CABA) Total Liabilities (2018 - 2026) Analysis & Trends
Cabaletta Bio's Total Liabilities history runs 8 years deep, the most recent figure standing at $53.0 million for Q4 2025.
- In Q4 2025, Total Liabilities rose 62.12% year-over-year to $53.0 million; the TTM figure through Dec 2025 stood at $53.0 million (up 62.12% YoY), while the FY2025 annual figure was $53.0 million, up 62.12% from the prior year.
- Total Liabilities for Q4 2025 stood at $53.0 million, up from $50.3 million in the prior quarter.
- The five-year high for Total Liabilities was $122.6 million in Q3 2021, with the low at $8.4 million in Q4 2021.
- The 5-year median for Total Liabilities is $38.1 million (2024), against an average of $50.5 million.
- The sharpest annual moves came in 2021 and 2025: Total Liabilities plunged 92.7% in 2021, then surged 157.1% in 2025.
- Cabaletta Bio's Total Liabilities stood at $8.4 million in 2021, then surged by 48.54% to $12.4 million in 2022, then jumped by 40.2% to $17.5 million in 2023, then soared by 87.43% to $32.7 million in 2024, then jumped by 62.12% to $53.0 million in 2025.
- Business Quant data shows CABA's Total Liabilities at $53.0 million in Q4 2025, $50.3 million in Q3 2025, and $46.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | 46.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.14 Mn |
| Dec 31, 2025 | 53.03 Mn |
| Sep 30, 2025 | 50.29 Mn |
| Jun 30, 2025 | 46.02 Mn |
| Mar 31, 2025 | 43.59 Mn |
| Dec 31, 2024 | 32.71 Mn |
| Sep 30, 2024 | 30.17 Mn |
| Jun 30, 2024 | 17.90 Mn |
| Mar 31, 2024 | 18.74 Mn |
| Dec 31, 2023 | 17.45 Mn |
| Sep 30, 2023 | 12.36 Mn |
| Jun 30, 2023 | 10.50 Mn |
| Mar 31, 2023 | 11.80 Mn |
| Dec 31, 2022 | 12.45 Mn |
| Sep 30, 2022 | 91.68 Mn |
| Jun 30, 2022 | 102.02 Mn |
| Mar 31, 2022 | 113.66 Mn |
| Dec 31, 2021 | 8.38 Mn |
| Sep 30, 2021 | 122.64 Mn |
| Jun 30, 2021 | 106.93 Mn |